Baxter Faces Securities Class Actions Over Novum Pump Disclosures as Lead Plaintiff Deadline Nears
Plaintiff firms say investors were misled about safety risks tied to Baxter’s Novum infusion pumps.
Overview
- Bernstein Liebhard announced a lawsuit on behalf of investors who bought Baxter shares from February 23, 2022 through July 30, 2025.
- Lowey Dannenberg reported filing an October 16, 2025 complaint alleging systemic Novum pump defects that caused underinfusion, overinfusion, or non‑delivery and led to serious injuries and deaths.
- The Lowey complaint claims Baxter’s customer alerts failed to fix underlying design flaws and that investors were harmed when the stock fell after adverse information emerged.
- Investor notices state that motions to serve as lead plaintiff are due by December 15, 2025.
- A separate notice from The Schall Law Firm cites a different class period focused on alleged concealment of supply‑chain problems and misleading earnings projections.